Erschienen in:
Blood Advances, 2 (2018) 19, Seite 2550-2553
Sprache:
Englisch
DOI:
10.1182/bloodadvances.2018020883
ISSN:
2473-9529;
2473-9537
Entstehung:
Anmerkungen:
Beschreibung:
Abstract New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post–hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.